Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Pankaj R Patel has submitted the disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 201118-11-2016
18-11-2016
Outcome of Board Meeting - Scheme of Arrangement
Cadila Healthcare Ltd has informed BSE that the Board of Directors of Cadila Healthcare Limited ('Company') at its meeting held on November 17, 2016, has considered and approved the Scheme of Arrangement between Cadila Healthcare Limited and Zydus Healthcare Limited and their respective shareholders and creditors ["Scheme"] under sections 391 to 394 of the Companies Act, 1956. Zydus Healthcare Limited is a wholly owned subsidiary of the Company....17-11-2016
Cadila develops India's first virus like particle vaccine for treating flu
CPL Biologicals, which has developed the vaccine, is a JV between Cadila and US-based Novavax17-11-2016
Presentation
Cadila Healthcare Ltd has informed BSE that the Company is going to participate in IDFC Investor Conference scheduled to be held on November 16, 2016. The presentation to be made to the investors is enclosed.15-11-2016
Zydus To Present New Scientific Data of Investigational Saroglitazar at the 2016 AASLD Liver Meeting in Boston, USA
Cadila Healthcare Ltd has submitted to BSE a copy of Press Release dated October 31, 2016 titled ''Zydus To Present New Scientific Data of Investigational Saroglitazar at the 2016 AASLD Liver Meeting in Boston, USA".31-10-2016
Cadila Healthcare profit falls 29% to Rs337.6 crore
Cadila Healthcare's revenue rose to Rs2,403.5 crore in September quarter from Rs2,394.9 crore a year ago26-10-2016
Announces Q2 Results (Standalone & Consolidated) & Limited Review Report (Standalone & Consolidated) for the Quarter ended September 30, 2016
Cadila Healthcare Ltd has announced the following results for the quarter ended September 30, 2016The Unaudited Standalone results for the Quarter ended September 30, 2016 The Company has posted a net profit of Rs. 1090 million for the quarter ended September 30, 2016 as compared to Rs. 6347 million for the quarter ended September 30, 2015. Total Income has decreased from Rs. 20201 million for the quarter ended September 30, 2015...26-10-2016
Post results conference call with investors/ analysts
Cadila Healthcare Ltd has informed BSE about Post results conference call with investors/ analysts.19-10-2016
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended September 30, 2016
Cadila Healthcare Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended September 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.12-10-2016
Shareholding for the Period Ended September 30, 2016
Cadila Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2016. For more details, kindly Click here12-10-2016